The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
The Role of FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases: Non-randomized Phase II Molecular Imaging Study
Jules Bordet Institute
50 participants
May 9, 2025
INTERVENTIONAL
Conditions
Summary
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery
Eligibility
Inclusion Criteria6
- Age above 18 years.
- Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT)
- Naïve for treatment or after neoadjuvant chemotherapy
- Scheduled for liver metastasis resection
- ECOG Performance status ≤2.
- Signed written informed consent
Exclusion Criteria3
- Non-resectable liver metastases
- Pregnant and lactating women
- Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Interventions
Patient will undergo FAPI PET/CT Prior to surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07109440